Pfizer Corporation

Patrick Michael Doerner Barbour

Li Ren

David A Moreno

Alex Andrew Kellum

James F Blake

Shelley Allen

Mark Laurence Boys

Joshua Ryan Dahlke

Jacob Matthew O'Leary

Ellen Ruth Laird

Dean Russell Kahn

Connor James Cowdrey

Sydney Taylor Blanche

Wesley Dewitt Clark

Tanna Marie Bettendorf

Ellen Margaret Knapp

Jennifer Lynn Fulton

Faith Elizabeth Witkos

Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, Rand L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, Rand Rare as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

Growing community of inventors

Westminster, CO, United States of America

Patrick Michael Doerner Barbour